Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1991 1
2000 2
2001 2
2002 2
2003 3
2004 1
2005 3
2006 7
2007 2
2008 6
2009 7
2010 7
2011 10
2012 15
2013 17
2014 18
2015 29
2016 34
2017 15
2018 27
2019 30
2020 41
2021 44
2022 40
2023 51
2024 15

Text availability

Article attribute

Article type

Publication date

Search Results

380 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: Aiboud
Page 1
Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study.
Matulonis UA, Lorusso D, Oaknin A, Pignata S, Dean A, Denys H, Colombo N, Van Gorp T, Konner JA, Marin MR, Harter P, Murphy CG, Wang J, Noble E, Esteves B, Method M, Coleman RL. Matulonis UA, et al. J Clin Oncol. 2023 May 1;41(13):2436-2445. doi: 10.1200/JCO.22.01900. Epub 2023 Jan 30. J Clin Oncol. 2023. PMID: 36716407 Free PMC article. Clinical Trial.
Mirvetuximab soravtansine (MIRV) is an antibody-drug conjugate targeting folate receptor alpha (FRalpha). SORAYA is a single-arm, phase II study evaluating efficacy and safety of MIRV in patients with PROC. METHODS: SORAYA enrolled FRalpha-high patients with PROC wh …
Mirvetuximab soravtansine (MIRV) is an antibody-drug conjugate targeting folate receptor alpha (FRalpha). SORAYA is a single-arm, pha …
Antibody-Drug Conjugates in Gynecologic Cancer.
Karpel HC, Powell SS, Pothuri B. Karpel HC, et al. Am Soc Clin Oncol Educ Book. 2023 May;43:e390772. doi: 10.1200/EDBK_390772. Am Soc Clin Oncol Educ Book. 2023. PMID: 37229642 Free article. Review.
In ovarian cancer, mirvetuximab soravtansine, an ADC targeting alpha-folate receptor (FRalpha), received US Food and Drug Administration (FDA) accelerated approval in November 2022 after data from the single-arm phase III SORAYA trial. A second ADC targeting FRalpha, STRO- …
In ovarian cancer, mirvetuximab soravtansine, an ADC targeting alpha-folate receptor (FRalpha), received US Food and Drug Administration (FD …
FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer.
Dilawari A, Shah M, Ison G, Gittleman H, Fiero MH, Shah A, Hamed SS, Qiu J, Yu J, Manheng W, Ricks TK, Pragani R, Arudchandran A, Patel P, Zaman S, Roy A, Kalavar S, Ghosh S, Pierce WF, Rahman NA, Tang S, Mixter BD, Kluetz PG, Pazdur R, Amiri-Kordestani L. Dilawari A, et al. Clin Cancer Res. 2023 Oct 2;29(19):3835-3840. doi: 10.1158/1078-0432.CCR-23-0991. Clin Cancer Res. 2023. PMID: 37212825
The VENTANA FOLR1 (FOLR-2.1) RxDx Assay was approved as a companion diagnostic device to select patients for this indication. Approval was based on Study 0417 (SORAYA, NCT04296890), a single-arm, multicenter trial. In 104 patients with measurable disease who received mirve …
The VENTANA FOLR1 (FOLR-2.1) RxDx Assay was approved as a companion diagnostic device to select patients for this indication. Approval was b …
Niacin.
Djadjo S, Bajaj T. Djadjo S, et al. 2023 Mar 20. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. 2023 Mar 20. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 31082080 Free Books & Documents.
Mirvetuximab soravtansine for platinum-resistant epithelial ovarian cancer.
Porter RL, Matulonis UA. Porter RL, et al. Expert Rev Anticancer Ther. 2023 Jul-Dec;23(8):783-796. doi: 10.1080/14737140.2023.2236793. Epub 2023 Jul 24. Expert Rev Anticancer Ther. 2023. PMID: 37458180 Review.
Mirvetuximab received accelerated approval by the United States Food and Drug Administration (FDA) in November 2022 based on the results of the SORAYA trial, which tested mirvetuximab for the treatment of patients with recurrent platinum resistant HGSOC with high FRalpha e …
Mirvetuximab received accelerated approval by the United States Food and Drug Administration (FDA) in November 2022 based on the results of …
Dendrimer Prodrugs.
da Silva Santos S, Igne Ferreira E, Giarolla J. da Silva Santos S, et al. Molecules. 2016 May 31;21(6):686. doi: 10.3390/molecules21060686. Molecules. 2016. PMID: 27258239 Free PMC article. Review.
Antibody-Drug Conjugates in Gynecologic Cancers.
Anastasio MK, Shuey S, Davidson BA. Anastasio MK, et al. Curr Treat Options Oncol. 2024 Jan;25(1):1-19. doi: 10.1007/s11864-023-01166-0. Epub 2024 Jan 3. Curr Treat Options Oncol. 2024. PMID: 38172449 Review.
Mirvetuximab soravtansine targets folate receptor alpha and is approved for use in patients with folate receptor alpha-positive, platinum-resistant, epithelial ovarian cancer based on results from the SORAYA trial. While there are no FDA-approved ADCs for the treatment of …
Mirvetuximab soravtansine targets folate receptor alpha and is approved for use in patients with folate receptor alpha-positive, platinum-re …
Inflammation in atherosclerosis.
Taleb S. Taleb S. Arch Cardiovasc Dis. 2016 Dec;109(12):708-715. doi: 10.1016/j.acvd.2016.04.002. Epub 2016 Aug 29. Arch Cardiovasc Dis. 2016. PMID: 27595467 Free article. Review.
Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine.
Hendershot A, Slabaugh M, Riaz KM, Moore KN, O'Malley DM, Matulonis U, Konecny GE. Hendershot A, et al. Gynecol Oncol Rep. 2023 Feb 28;47:101155. doi: 10.1016/j.gore.2023.101155. eCollection 2023 Jun. Gynecol Oncol Rep. 2023. PMID: 37102083 Free PMC article. Review.
Pooled safety analysis of 464 MIRV-treated patients across 3 trials, including the phase 2 SORAYA study, found that 50% of patients had 1 ocular AEs of interest (AEIs) of blurred vision or keratopathy, the majority being grade 2. ...
Pooled safety analysis of 464 MIRV-treated patients across 3 trials, including the phase 2 SORAYA study, found that 50% of patients h …
Mu-CT.
Robinson S, Suomalainen A, Kortesniemi M. Robinson S, et al. Eur J Radiol. 2005 Nov;56(2):185-91. doi: 10.1016/j.ejrad.2005.03.022. Eur J Radiol. 2005. PMID: 16233892 Review.
380 results